Identifying the earliest somatic changes in prostate cancer can give important insights into
tumor evolution and aids in stratifying high-from low-risk disease. We integrated whole …

Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of
prostate cancer. To compare the genomic alteration landscapes of EO-PCA with" …

DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate
cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic …

Background Genomic analyses of hundreds of prostate tumors have defined a diverse
landscape of mutations and genome rearrangements, but the transcriptomic effect of this …

Background Global disparities in prostate cancer (PCa) incidence highlight the urgent need
to identify genomic abnormalities in prostate tumors in different ethnic populations including …

Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

Annotation of prostate cancer genomes provides a foundation for discoveries that can
impact disease understanding and treatment. Concordant assessment of DNA copy number …

To understand functional consequences of genetic and transcriptional aberrations in
prostate cancer, the proteomic changes during disease formation and progression need to …

Purpose A long natural history and a predominant osseous pattern of metastatic spread are
impediments to the adoption of precision medicine in patients with prostate cancer. To …

Comprehensive genomic studies have delineated key driver mutations linked to disease
progression for most cancers. However, corresponding transcriptional changes remain …